Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Change in Accured Expenses (2022 - 2025)

Envoy Medical's Change in Accured Expenses history spans 4 years, with the latest figure at -$96000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 107.37% year-over-year to -$96000.0; the TTM value through Sep 2025 reached $11000.0, up 101.33%, while the annual FY2024 figure was -$241000.0, 156.38% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$96000.0 at Envoy Medical, down from $113000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.3 million in Q3 2024 and bottomed at -$982000.0 in Q2 2024.
  • The 4-year median for Change in Accured Expenses is -$96000.0 (2025), against an average of $933.33.
  • The largest YoY upside for Change in Accured Expenses was 361.4% in 2023 against a maximum downside of 432.49% in 2023.
  • A 4-year view of Change in Accured Expenses shows it stood at $237000.0 in 2022, then plummeted by 432.49% to -$788000.0 in 2023, then surged by 73.98% to -$205000.0 in 2024, then surged by 53.17% to -$96000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Change in Accured Expenses are -$96000.0 (Q3 2025), $113000.0 (Q2 2025), and $199000.0 (Q1 2025).